These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25151619)

  • 1. Pathogenic tau species drive a psychosis-like phenotype in a mouse model of Alzheimer's disease.
    Koppel J; Jimenez H; Azose M; D'Abramo C; Acker C; Buthorn J; Greenwald BS; Lewis J; Lesser M; Liu Z; Davies P
    Behav Brain Res; 2014 Dec; 275():27-33. PubMed ID: 25151619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease.
    Pietropaolo S; Feldon J; Yee BK
    Behav Neurosci; 2008 Aug; 122(4):733-47. PubMed ID: 18729626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510).
    Yang D; Xie Z; Stephenson D; Morton D; Hicks CD; Brown TM; Sriram R; O'Neill S; Raunig D; Bocan T
    Neuroimage; 2011 Feb; 54(4):2652-8. PubMed ID: 21035554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice.
    García-Mesa Y; López-Ramos JC; Giménez-Llort L; Revilla S; Guerra R; Gruart A; Laferla FM; Cristòfol R; Delgado-García JM; Sanfeliu C
    J Alzheimers Dis; 2011; 24(3):421-54. PubMed ID: 21297257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal genotype influences behavioral development of 3×Tg-AD mouse pups.
    Blaney CE; Gunn RK; Stover KR; Brown RE
    Behav Brain Res; 2013 Sep; 252():40-8. PubMed ID: 23711927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease.
    Wang H; He J; Zhang R; Zhu S; Wang J; Kong L; Tan Q; Li XM
    Behav Brain Res; 2012 Jul; 233(1):237-43. PubMed ID: 22595040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
    Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
    J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice.
    Kreilaus F; Masanetz R; Watt G; Przybyla M; Ittner A; Ittner L; Karl T
    Behav Brain Res; 2021 Jan; 397():112943. PubMed ID: 33017638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.
    Blackmore T; Meftah S; Murray TK; Craig PJ; Blockeel A; Phillips K; Eastwood B; O'Neill MJ; Marston H; Ahmed Z; Gilmour G; Gastambide F
    Alzheimers Res Ther; 2017 Sep; 9(1):77. PubMed ID: 28931441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo axonal transport deficits in a mouse model of fronto-temporal dementia.
    Majid T; Ali YO; Venkitaramani DV; Jang MK; Lu HC; Pautler RG
    Neuroimage Clin; 2014; 4():711-7. PubMed ID: 24936422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease.
    Chang SH; Jung IS; Han GY; Kim NH; Kim HJ; Kim CW
    Biochem Biophys Res Commun; 2013 Jan; 430(2):670-5. PubMed ID: 23211594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.
    Sui X; Ren X; Huang P; Li S; Ma Q; Ying M; Ni J; Liu J; Yang X
    J Alzheimers Dis; 2014; 40(3):575-86. PubMed ID: 24496070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.
    Laurent C; Eddarkaoui S; Derisbourg M; Leboucher A; Demeyer D; Carrier S; Schneider M; Hamdane M; Müller CE; Buée L; Blum D
    Neurobiol Aging; 2014 Sep; 35(9):2079-90. PubMed ID: 24780254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
    Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
    Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.